Analysts Offer Predictions for Aduro Biotech, Inc.’s Q3 2017 Earnings (NASDAQ:ADRO)
Aduro Biotech, Inc. (NASDAQ:ADRO) – Research analysts at Leerink Swann lifted their Q3 2017 EPS estimates for shares of Aduro Biotech in a report issued on Thursday. Leerink Swann analyst S. Fernandez now forecasts that the biotechnology company will earn ($0.41) per share for the quarter, up from their prior estimate of ($0.43). Leerink Swann also issued estimates for Aduro Biotech’s Q4 2017 earnings at ($0.50) EPS, FY2017 earnings at ($1.51) EPS, FY2018 earnings at ($1.26) EPS, FY2019 earnings at ($0.78) EPS and FY2020 earnings at ($1.11) EPS.
Several other equities research analysts have also commented on ADRO. Rodman & Renshaw started coverage on shares of Aduro Biotech in a research report on Monday, May 1st. They set a “buy” rating and a $18.00 target price on the stock. HC Wainwright started coverage on shares of Aduro Biotech in a research report on Monday, May 1st. They set a “buy” rating and a $18.00 target price on the stock. Zacks Investment Research lowered shares of Aduro Biotech from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 2nd. Canaccord Genuity restated a “buy” rating and set a $30.00 target price on shares of Aduro Biotech in a research report on Wednesday, May 3rd. Finally, Cowen and Company initiated coverage on shares of Aduro Biotech in a research report on Tuesday, July 18th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $19.00.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/09/analysts-offer-predictions-for-aduro-biotech-inc-s-q3-2017-earnings-nasdaqadro.html.
Aduro Biotech (ADRO) opened at 12.30 on Monday. The firm’s market capitalization is $906.21 million. Aduro Biotech has a 52-week low of $8.75 and a 52-week high of $16.18. The firm’s 50-day moving average is $12.28 and its 200-day moving average is $10.96.
Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.02. The company had revenue of $5.90 million for the quarter, compared to analyst estimates of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The business’s revenue was down 84.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.03 earnings per share.
Large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its stake in Aduro Biotech by 9.1% in the first quarter. Wellington Management Group LLP now owns 9,448,529 shares of the biotechnology company’s stock valued at $101,571,000 after buying an additional 791,770 shares in the last quarter. Vanguard Group Inc. raised its stake in Aduro Biotech by 2.1% in the first quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock valued at $25,617,000 after buying an additional 48,840 shares in the last quarter. State Street Corp raised its stake in Aduro Biotech by 1.3% in the fourth quarter. State Street Corp now owns 573,804 shares of the biotechnology company’s stock valued at $6,544,000 after buying an additional 7,597 shares in the last quarter. Norges Bank acquired a new stake in Aduro Biotech during the fourth quarter valued at approximately $3,266,000. Finally, Geode Capital Management LLC raised its stake in Aduro Biotech by 6.0% in the first quarter. Geode Capital Management LLC now owns 262,809 shares of the biotechnology company’s stock valued at $2,825,000 after buying an additional 14,946 shares in the last quarter. Institutional investors and hedge funds own 35.60% of the company’s stock.
In related news, insider Thomas W. Dubensky sold 144,301 shares of the business’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $10.03, for a total value of $1,447,339.03. Following the sale, the insider now directly owns 117,871 shares in the company, valued at approximately $1,182,246.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Thomas W. Dubensky sold 5,699 shares of the business’s stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $9.92, for a total transaction of $56,534.08. Following the completion of the sale, the insider now owns 41,300 shares in the company, valued at $409,696. The disclosure for this sale can be found here. Insiders sold a total of 419,205 shares of company stock worth $4,410,591 over the last quarter. Insiders own 6.60% of the company’s stock.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.